DCLA
TRAW icon

Douglas C. Lane & Associates’s Traws Pharma TRAW Stock Holding History

Douglas C. Lane & Associates’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$67K Buy
+1
New +$74.1K ﹤0.01% 219

Other funds holding TRAW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Douglas C. Lane & Associates's TRAW Position: Q4 2015 in Review

Douglas C. Lane & Associates opened a new position in Traws Pharma (TRAW) in Q4 2015: 1 share worth $67K. The stake represents ﹤0.01% of the portfolio and ranks #219 among its holdings.

13 funds tracked by Wall St. Rank hold TRAW as of Q4 2015.

  • Douglas C. Lane & Associates held 1 share of Traws Pharma worth $67K as of Q4 2015.
  • Traws Pharma was a new Douglas C. Lane & Associates position in Q4 2015.
  • Traws Pharma made up ﹤0.01% of Douglas C. Lane & Associates's portfolio in Q4 2015, its #219 holding.
  • 13 funds tracked by Wall St. Rank held Traws Pharma as of Q4 2015.

Based on Douglas C. Lane & Associates's 13F filing for Q4 2015, filed 25 Jan 2016.